![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » China’s Sinopharm Begins Phase 3 COVID-19 Vaccine Trial in United Arab Emirates
China’s Sinopharm Begins Phase 3 COVID-19 Vaccine Trial in United Arab Emirates
![COVID-19 Clinical Trial](https://www.fdanews.com/ext/resources/test/Drug-Images4/COVID-19-CLINICAL-TRIAL.gif?t=1585696642&width=430)
China-owned pharmaceutical company Sinopharm has begun a phase 3 clinical trial of its COVID-19 vaccine candidate in the United Arab Emirates.
The study will evaluate two formulations of the vaccine in 15,000 volunteers ages 18-60 and is expected to last for three to six months.
Sinopharm’s inactivated COVID-19 vaccine demonstrated a 100 percent immune response in phase 1 and 2 clinical trials.
Upcoming Events
-
21Oct